A controlled trial of amino acid therapy in amyotrophic lateral sclerosis: I. Clinical, functional, and maximum isometric torque data
The DOI matches its Crossref record.
Abstract
We conducted a two center, double-blind, placebo-controlled treatment trial with oral branched chain amino acids (BCAA) (L-leucine 12 g, L-isoleucine 8 g, and L-valine 6.4 g daily) or L-threonine (4 g daily) with pyridoxal phosphate (160 mg daily) for six months in patients with amyotrophic lateral sclerosis (ALS). The effect of treatment on disease progression was estimated every two months by recording clinical muscle strength, maximum isometric muscle torque in selected muscles, forced vital capacity (FVC), activities of daily living pertaining to the upper and lower limbs, and timed tasks. Ninety-five patients were randomized to receive BCAA (n = 31), L-threonine (n = 32), or placebo (n = 32), of whom 77 (81%) completed the trial. Mean weight loss in the placebo group was 1.1 kg and in the L-threonine group was 3.2 kg; the BCAA group gained 0.2 kg (p = 0.04). The estimated decline in FVC was about 2.5 times greater in the BCAA and L-threonine groups as compared to placebo (p = 0.03). Otherwise, no significant differences were found in the changes observed in clinical, functional, timed, or maximum torque measures among treatment groups. The amino acids were well tolerated. The results of our study failed to show a beneficial effect of BCAA or L-threonine treatment for six months on the disease course in ALS. The higher rate of loss of pulmonary function in patients treated with BCAA or L-threonine may have been due to chance, but an adverse effect of these amino acids cannot be ruled out.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
Branched-Chain Amino Acids and Brain Function
Fernstrom, J. D. (2005) · The Journal of Nutrition · doi:10.1093/jn/135.6.1539s · Cited by 514
“4 g BCAA administered daily in divided doses for 6 mo, BCAA treatment was noted to accelerate the decline in respiratory function (50), ultimately, the most common cause of death in ALS patients (46).”
BackgroundBelli, S., & Vanacore, N. (2005) · European Journal of Epidemiology · doi:10.1007/s10654-004-6879-7 · Cited by 140
Are professional soccer players at higher risk for ALS?
Beghi, E. (2013) · Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration · doi:10.3109/21678421.2013.809764 · Cited by 39
Elliott, J. E., Keil, A. T., Mithani, S., Gill, J. M., O’Neil, M. E., Cohen, A. S., & Lim, M. M. (2022) · Frontiers in Systems Neuroscience · doi:10.3389/fnsys.2022.854874 · Cited by 22
Possible therapy for ALS based on the cyanobacteria/BMAA hypothesis
Bradley, W. G. (2009) · Amyotrophic Lateral Sclerosis · doi:10.3109/17482960903285951 · Cited by 5
Metadata
- Authors
- Tandan, R., Bromberg, M. B., Forshew, D., Fries, T. J., Badger, G. J., Carpenter, J., Krusinski, P. B., Betts, E. F., Arciero, K., & Nau, K.
- Venue
- Neurology
- Published
- 1996-11
- Volume
- 47
- Issue
- 5
- Pages
- 1220-1226
- ISSN
- 0028-3878 (ISSN-L)
- 1526-632X
- OpenAlex
- W2160628227
- Cited by
- 71
- References
- 0
- FWCI
- 2.00
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: A controlled trial of amino acid therapy in amyotrophic lateral sclerosis: I. Clinical, functional, and maximum isometric torque data. https://app.cochat.ai/papers/10.1212/wnl.47.5.1220
- The paper
- Tandan, R., Bromberg, M. B., Forshew, D., Fries, T. J., Badger, G. J., Carpenter, J., Krusinski, P. B., Betts, E. F., Arciero, K., & Nau, K. (1996). A controlled trial of amino acid therapy in amyotrophic lateral sclerosis: I. Clinical, functional, and maximum isometric torque data. Neurology. https://doi.org/10.1212/wnl.47.5.1220
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.